C8 2lr2444

By: Delegates V. Turner, Braveboy, Cane, Costa, Donoghue, Elliott, Frank, Frush, Gaines, Healey, Holmes, Howard, Hubbard, Ivey, Kach, Kipke, Krebs, Morhaim, Nathan-Pulliam, Niemann, Oaks, Pena-Melnyk, Proctor, Ready, Reznik, B. Robinson, Ross, Rudolph, Summers, Tarrant, F. Turner, Valderrama, Vallario, Vaughn, and Walker

Introduced and read first time: February 10, 2012 Assigned to: Health and Government Operations

A BILL ENTITLED

1 AN ACT concerning

2

Economic Development - Sickle Cell Disease Research Program

3 FOR the purpose of establishing the Sickle Cell Disease Research Program to be 4 administered by the Maryland Technology Development Corporation to provide 5 grants for certain sickle cell disease research projects; establishing the purposes 6 of the Program; establishing the Sickle Cell Disease Research Fund in the 7 Corporation; providing for the purpose and composition of the Fund; requiring 8 the Executive Director of the Corporation or the Executive Director's designee to 9 administer the Fund; requiring the State Treasurer to invest money in the Fund; providing that earnings of the Fund shall be credited to the Fund; 10 establishing certain types of grants to be awarded under the Program; requiring 11 12 the Corporation to adopt certain regulations; requiring the Corporation to 13 include certain information in a certain report to the Governor and General Assembly: exempting the Fund from a certain provision of law requiring 14 15 interest on State money in special funds to accrue to the General Fund of the 16 State; defining certain terms; and generally relating to the creation of a 17 program for sickle cell disease research.

18 BY adding to

19

21

25

Article – Economic Development

Section 10–454 through 10–459 to be under the new part "Part V. Sickle Cell

Disease Research Program"

22 Annotated Code of Maryland

23 (2008 Volume and 2011 Supplement)

24 BY repealing and reenacting, with amendments,

Article – State Finance and Procurement

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



29

DISEASE RESEARCH AND TREATMENT.

	2 HOUSE BILL 1020				
1 2 3	Section 6–226(a)(2)(ii)62. and 63. Annotated Code of Maryland (2009 Replacement Volume and 2011 Supplement)				
4 5 6 7 8	BY adding to Article – State Finance and Procurement Section 6–226(a)(2)(ii)64. Annotated Code of Maryland (2009 Replacement Volume and 2011 Supplement)				
9 10	SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, That the Laws of Maryland read as follows:				
11	Article – Economic Development				
12	10-452. RESERVED.				
13	10-453. RESERVED.				
14	PART V. SICKLE CELL DISEASE RESEARCH PROGRAM.				
15	10–454.				
16 17	(A) IN THIS PART THE FOLLOWING WORDS HAVE THE MEANINGS INDICATED.				
18 19	(B) "FUND" MEANS THE SICKLE CELL DISEASE RESEARCH FUND ESTABLISHED UNDER § 10–456 OF THIS SUBTITLE.				
20 21	(c) "Program" means the Sickle Cell Disease Research Program established under § $10-455$ of this subtitle.				
22	10-455.				
23	(A) THERE IS A SICKLE CELL DISEASE RESEARCH PROGRAM.				
24	(B) THE PURPOSE OF THE PROGRAM IS TO:				
25 26 27	(1) PROMOTE MILESTONE-DRIVEN TRANSLATIONAL RESEARCH USING BONE MARROW AND UMBILICAL CORD BLOOD TO DEVELOP CURES FOR SICKLE CELL DISEASE; AND				
28	(2) ESTABLISH THE STATE AS A KEY LOCATION FOR SICKLE CELL				

- 1 (C) THE CORPORATION SHALL ADMINISTER THE PROGRAM.
- 2 **10–456.**
- 3 (A) THERE IS A SICKLE CELL DISEASE RESEARCH FUND IN THE 4 CORPORATION.
- 5 (B) THE PURPOSE OF THE FUND IS TO PROVIDE GRANTS AND LOANS TO
 6 PUBLIC AND PRIVATE ENTITIES IN THE STATE TO DEVELOP CURES FOR SICKLE
 7 CELL DISEASE USING BONE MARROW AND UMBILICAL CORD BLOOD.
- 8 (C) (1) THE FUND IS A SPECIAL, NONLAPSING FUND THAT IS NOT 9 SUBJECT TO § 7–302 OF THE STATE FINANCE AND PROCUREMENT ARTICLE.
- 10 (2) THE STATE TREASURER SHALL HOLD THE FUND SEPARATELY, AND THE COMPTROLLER SHALL ACCOUNT FOR THE FUND.
- 12 (D) THE FUND CONSISTS OF:
- 13 (1) MONEY APPROPRIATED IN THE STATE BUDGET TO THE FUND;
- 14 **AND**
- 15 (2) ANY OTHER MONEY FROM ANY OTHER SOURCE ACCEPTED FOR 16 THE BENEFIT OF THE FUND.
- 17 (E) THE EXECUTIVE DIRECTOR OF THE CORPORATION, OR THE 18 EXECUTIVE DIRECTOR'S DESIGNEE, SHALL ADMINISTER THE FUND IN
- 19 ACCORDANCE WITH THIS PART AND OTHER APPLICABLE LAW.
- 20 (F) THE FUND SHALL BE USED TO COVER THE COSTS OF THE
- 21 PROGRAM, INCLUDING ANY GRANTS AND LOANS THAT ARE AWARDED TO
- 22 ELIGIBLE RECIPIENTS.
- 23 (G) (1) THE STATE TREASURER SHALL INVEST THE MONEY OF THE 24 FUND IN THE SAME MANNER AS OTHER STATE MONEY MAY BE INVESTED.
- 25 (2) ANY INVESTMENT EARNINGS OF THE FUND SHALL BE 26 CREDITED TO THE FUND.
- 27 (H) (1) THE GOVERNOR MAY INCLUDE IN THE STATE BUDGET BILL 28 FOR EACH FISCAL YEAR AN APPROPRIATION TO THE FUND.

- 4 **HOUSE BILL 1026** EXPENDITURES FROM THE FUND MAY BE MADE ONLY IN 1 **(2)** 2 ACCORDANCE WITH AN APPROPRIATION BY THE GENERAL ASSEMBLY IN THE 3 STATE BUDGET OR BY AN APPROVED BUDGET AMENDMENT. 10-457. 4 WITHIN THE SICKLE CELL DISEASE RESEARCH PROGRAM, SUBJECT TO 5 6 AVAILABLE FUNDING, THE CORPORATION SHALL AWARD CAPITAL AND 7 OPERATING GRANTS FROM THE FUND TO PUBLIC OR PRIVATE SECTOR ENTITIES 8 IN THE STATE TO DEVELOP A CURE FOR SICKLE CELL DISEASE THAT WILL BE 9 WIDELY AVAILABLE TO A MAJORITY OF INDIVIDUALS DIAGNOSED WITH THE 10 DISEASE. 11 **10–458.** 12 (A) THE CORPORATION SHALL ADOPT REGULATIONS TO ESTABLISH: 13 **(1)** A COMPETITIVE APPLICATION PROCESS; AND CRITERIA AND PROCEDURES FOR AWARDING GRANTS FROM 14 **(2)** 15 THE FUND TO ELIGIBLE RECIPIENTS. 16 IN ACCORDANCE WITH THIS PART, ALL PUBLIC AND PRIVATE **(1)** 17 ENTITIES IN THE STATE MAY BE ELIGIBLE RECIPIENTS OF GRANTS. 18 **(2)** PRIORITY FOR THE AWARD OF ANY GRANT SHALL BE GIVEN 19 TO THOSE PROJECTS THAT ARE MOST LIKELY TO RESULT IN A CURE FOR SICKLE CELL DISEASE THAT WILL BE WIDELY AVAILABLE TO A MAJORITY OF 20 21 INDIVIDUALS DIAGNOSED WITH THE DISEASE. 22 10-459. 23 THE CORPORATION SHALL INCLUDE, AS PART OF ITS ANNUAL REPORT TO 24THE GOVERNOR AND GENERAL ASSEMBLY UNDER § 10-415 OF THIS SUBTITLE, A DETAILED DESCRIPTION OF THE GRANTS AWARDED UNDER THIS PART. 25**Article - State Finance and Procurement**
- 26
- 6-226.27
- 28(a) (2) (ii) The provisions of subparagraph (i) of this paragraph do not 29 apply to the following funds:
 - 62. Veterans Trust Fund; [and]

1		63.	Transportation Trust Fund; AND
2		64.	SICKLE CELL DISEASE RESEARCH FUND.
3 4	SECTION 2. AND October 1, 2012.	BE IT	FURTHER ENACTED, That this Act shall take effect